KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Accounts Payables: 2009-2025

Historic Accounts Payables for Teva Pharmaceutical Industries (TEVA) over the last 9 years, with Sep 2025 value amounting to $2.4 billion.

  • Teva Pharmaceutical Industries' Accounts Payables fell 0.67% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year decrease of 0.67%. This contributed to the annual value of $2.2 billion for FY2024, which is 15.33% down from last year.
  • Teva Pharmaceutical Industries' Accounts Payables amounted to $2.4 billion in Q3 2025, which was down 5.72% from $2.5 billion recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Accounts Payables ranged from a high of $2.6 billion in Q4 2023 and a low of $1.5 billion during Q3 2021.
  • In the last 3 years, Teva Pharmaceutical Industries' Accounts Payables had a median value of $2.4 billion in 2024 and averaged $2.4 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Accounts Payables skyrocketed by 39.45% in 2023 and then decreased by 15.33% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Accounts Payables (Quarterly) stood at $1.7 billion in 2021, then grew by 11.92% to $1.9 billion in 2022, then surged by 37.89% to $2.6 billion in 2023, then declined by 15.33% to $2.2 billion in 2024, then dropped by 0.67% to $2.4 billion in 2025.
  • Its Accounts Payables stands at $2.4 billion for Q3 2025, versus $2.5 billion for Q2 2025 and $2.3 billion for Q1 2025.